Kondo H, Tanaka N, Naomoto Y, Orita K
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1836-40.
The development of useful therapy for the peritonitis carcinomatosa of gastrointestinal cancer is an important theme in cancer therapy. We developed an experimental model of peritonitis carcinomatosa in nude mice transplanted intraperitoneally human colon cancer cells. In this study, we investigated combined effect of human recombinant interferon-beta (rIFN-beta) and recombinant interferon-gamma (rIFN-gamma) in vivo using this model. The result indicate that each rIFN-beta and rIFN-gamma showed a significant prolonged survival compared with the control group (mean survival days: 41.8 +/- 5.0 days). Furthermore, combined administration of rIFN-beta and rIFN-gamma showed a marked prolonged survival (mean survival days: 114.0 +/- 7.4 days) compared with rIFN-beta or rIFN-gamma alone. These results suggest that a combined treatment of rIFN-beta and rIFN-gamma may be useful against peritonitis carcinomatosa of gastrointestinal cancer.
开发针对胃肠道癌腹膜癌的有效治疗方法是癌症治疗中的一个重要课题。我们建立了一个在裸鼠体内腹腔移植人结肠癌细胞的腹膜癌实验模型。在本研究中，我们使用该模型研究了人重组干扰素-β（rIFN-β）和重组干扰素-γ（rIFN-γ）在体内的联合作用。结果表明，与对照组相比，rIFN-β和rIFN-γ各自均显著延长了生存期（平均生存期：41.8±5.0天）。此外，与单独使用rIFN-β或rIFN-γ相比，联合使用rIFN-β和rIFN-γ显著延长了生存期（平均生存期：114.0±7.4天）。这些结果表明，rIFN-β和rIFN-γ联合治疗可能对胃肠道癌腹膜癌有效。
